CAN RED CELL DISTRIBUTION WIDTH BE A NEW PARAMETER FOR PREDICTING HIGHER CD34+ CELL COUNT IN THE HARVEST?
(Abstract release date: 05/19/16)
EHA Library. Gunduz E. 06/09/16; 135092; PB2192
Prof. Eren Gunduz
Contributions
Contributions
Abstract
Abstract: PB2192
Type: Publication Only
Background
The red cell distribution width (RDW) is a simple and unexpensive parameter and is traditionally used for differential diagnosis of anemias. However, the number of articles mentioning about the relationship between RDW and human disorders has increased over the past decades. In tranplantation practice, the peripheral blood is the most common source of hematopoietic stem cells. There are many factors affecting the success of stem cell mobilization.
Aims
In this study, we tried to find a relationship between increased RDW and CD34+ cell count in the harvest.
Methods
Fifty patients who underwent stem cell mobilization between March 2014 and October 2015 are included in the study. Mean age was 56.82± 10 years, 28 (%56) patients were male and 22 (%44) patients were female. Diagnosis were multiple myeloma (n=32), non Hodgkin lymphoma (n=9), Hodgkin lymphoma (n=6), primary amyloidosis (n=1), Waldenstrom’s macroglobulinemia (n=1) and testicular carcinoma (n=1). Mobilization regimens were cyclophosphamide plus G-CSF in 35 (%70) patients, G-CSF alone in 2 (%4) patients, etoposide plus G-CSF in 2 (%4) patients and salvage chemotherapy plus G-CSF in 11 (%22) patients. Five (%10) patients had a history of radiotherapy. Bone marrow infiltration for patients except myeloma was found in 6 (%35) patients. Patients received mean 1.61± 0.6 lines and 4.94±2.6 courses of chemotherapy.
Results
RDW was not correlated with peripheral blood CD34+ cell count (r=0.064, p=0.75, n=28) and CD34+ cell count in the harvest (r=-0.14, p=0.34, n=50). Other parameters previously reported to affect stem cell mobilization (age, weight, number of chemotherapy courses before mobilization, hemoglobin, white blood cell count, absolute neutrophil count, absolute lymphocyte count, platelet count, albumin, LDH) were also evaluated. Peripheral blood CD34+ cell count (r=0.694, p=0.001, n=50) and the number of chemotherapy courses before mobilization (r=-0.451, p=0.008, n=28) were found as the only parameters that affect CD34+ cell count in the harvest. In order to assess the effect of increased RDW on the CD34+ cell count in the harvest; above 16 was set as a cut-off for increased RDW and patients were divided into 2 groups. Sex, primary diagnosis, stage, bone marrow infiltration, mobilization regimen, chemotherapy courses, radiotherapy, comorbidities, number of leukapheresis days were not different between two groups. LDH was the only parameter different between 2 groups. It was found higher in the increased RDW group (p=0.005). Although peripheral blood CD34+ cell count and CD34+ cell count in the harvest were not different statistically between 2 groups, the numbers were lower in the increased RDW group (10.48±5.94 vs 8.07±5.01).RDW was not correlated with peripheral blood CD34+ cell count and CD34+ cell count in the harvest in both groups.
Conclusion
To our knowledge, this is the first study evaluating the relationship between RDW and stem cell mobilization in cancer patients. Although it has not been definitely established, it seems reasonable to suggest using RDW far beyond the differential diagnosis of anemias. Stem cell mobilization can be a potential candidate in this era.
Session topic: E-poster
Keyword(s): CD34+ cells, Stem cell mobilization
Type: Publication Only
Background
The red cell distribution width (RDW) is a simple and unexpensive parameter and is traditionally used for differential diagnosis of anemias. However, the number of articles mentioning about the relationship between RDW and human disorders has increased over the past decades. In tranplantation practice, the peripheral blood is the most common source of hematopoietic stem cells. There are many factors affecting the success of stem cell mobilization.
Aims
In this study, we tried to find a relationship between increased RDW and CD34+ cell count in the harvest.
Methods
Fifty patients who underwent stem cell mobilization between March 2014 and October 2015 are included in the study. Mean age was 56.82± 10 years, 28 (%56) patients were male and 22 (%44) patients were female. Diagnosis were multiple myeloma (n=32), non Hodgkin lymphoma (n=9), Hodgkin lymphoma (n=6), primary amyloidosis (n=1), Waldenstrom’s macroglobulinemia (n=1) and testicular carcinoma (n=1). Mobilization regimens were cyclophosphamide plus G-CSF in 35 (%70) patients, G-CSF alone in 2 (%4) patients, etoposide plus G-CSF in 2 (%4) patients and salvage chemotherapy plus G-CSF in 11 (%22) patients. Five (%10) patients had a history of radiotherapy. Bone marrow infiltration for patients except myeloma was found in 6 (%35) patients. Patients received mean 1.61± 0.6 lines and 4.94±2.6 courses of chemotherapy.
Results
RDW was not correlated with peripheral blood CD34+ cell count (r=0.064, p=0.75, n=28) and CD34+ cell count in the harvest (r=-0.14, p=0.34, n=50). Other parameters previously reported to affect stem cell mobilization (age, weight, number of chemotherapy courses before mobilization, hemoglobin, white blood cell count, absolute neutrophil count, absolute lymphocyte count, platelet count, albumin, LDH) were also evaluated. Peripheral blood CD34+ cell count (r=0.694, p=0.001, n=50) and the number of chemotherapy courses before mobilization (r=-0.451, p=0.008, n=28) were found as the only parameters that affect CD34+ cell count in the harvest. In order to assess the effect of increased RDW on the CD34+ cell count in the harvest; above 16 was set as a cut-off for increased RDW and patients were divided into 2 groups. Sex, primary diagnosis, stage, bone marrow infiltration, mobilization regimen, chemotherapy courses, radiotherapy, comorbidities, number of leukapheresis days were not different between two groups. LDH was the only parameter different between 2 groups. It was found higher in the increased RDW group (p=0.005). Although peripheral blood CD34+ cell count and CD34+ cell count in the harvest were not different statistically between 2 groups, the numbers were lower in the increased RDW group (10.48±5.94 vs 8.07±5.01).RDW was not correlated with peripheral blood CD34+ cell count and CD34+ cell count in the harvest in both groups.
Conclusion
To our knowledge, this is the first study evaluating the relationship between RDW and stem cell mobilization in cancer patients. Although it has not been definitely established, it seems reasonable to suggest using RDW far beyond the differential diagnosis of anemias. Stem cell mobilization can be a potential candidate in this era.
Session topic: E-poster
Keyword(s): CD34+ cells, Stem cell mobilization
Abstract: PB2192
Type: Publication Only
Background
The red cell distribution width (RDW) is a simple and unexpensive parameter and is traditionally used for differential diagnosis of anemias. However, the number of articles mentioning about the relationship between RDW and human disorders has increased over the past decades. In tranplantation practice, the peripheral blood is the most common source of hematopoietic stem cells. There are many factors affecting the success of stem cell mobilization.
Aims
In this study, we tried to find a relationship between increased RDW and CD34+ cell count in the harvest.
Methods
Fifty patients who underwent stem cell mobilization between March 2014 and October 2015 are included in the study. Mean age was 56.82± 10 years, 28 (%56) patients were male and 22 (%44) patients were female. Diagnosis were multiple myeloma (n=32), non Hodgkin lymphoma (n=9), Hodgkin lymphoma (n=6), primary amyloidosis (n=1), Waldenstrom’s macroglobulinemia (n=1) and testicular carcinoma (n=1). Mobilization regimens were cyclophosphamide plus G-CSF in 35 (%70) patients, G-CSF alone in 2 (%4) patients, etoposide plus G-CSF in 2 (%4) patients and salvage chemotherapy plus G-CSF in 11 (%22) patients. Five (%10) patients had a history of radiotherapy. Bone marrow infiltration for patients except myeloma was found in 6 (%35) patients. Patients received mean 1.61± 0.6 lines and 4.94±2.6 courses of chemotherapy.
Results
RDW was not correlated with peripheral blood CD34+ cell count (r=0.064, p=0.75, n=28) and CD34+ cell count in the harvest (r=-0.14, p=0.34, n=50). Other parameters previously reported to affect stem cell mobilization (age, weight, number of chemotherapy courses before mobilization, hemoglobin, white blood cell count, absolute neutrophil count, absolute lymphocyte count, platelet count, albumin, LDH) were also evaluated. Peripheral blood CD34+ cell count (r=0.694, p=0.001, n=50) and the number of chemotherapy courses before mobilization (r=-0.451, p=0.008, n=28) were found as the only parameters that affect CD34+ cell count in the harvest. In order to assess the effect of increased RDW on the CD34+ cell count in the harvest; above 16 was set as a cut-off for increased RDW and patients were divided into 2 groups. Sex, primary diagnosis, stage, bone marrow infiltration, mobilization regimen, chemotherapy courses, radiotherapy, comorbidities, number of leukapheresis days were not different between two groups. LDH was the only parameter different between 2 groups. It was found higher in the increased RDW group (p=0.005). Although peripheral blood CD34+ cell count and CD34+ cell count in the harvest were not different statistically between 2 groups, the numbers were lower in the increased RDW group (10.48±5.94 vs 8.07±5.01).RDW was not correlated with peripheral blood CD34+ cell count and CD34+ cell count in the harvest in both groups.
Conclusion
To our knowledge, this is the first study evaluating the relationship between RDW and stem cell mobilization in cancer patients. Although it has not been definitely established, it seems reasonable to suggest using RDW far beyond the differential diagnosis of anemias. Stem cell mobilization can be a potential candidate in this era.
Session topic: E-poster
Keyword(s): CD34+ cells, Stem cell mobilization
Type: Publication Only
Background
The red cell distribution width (RDW) is a simple and unexpensive parameter and is traditionally used for differential diagnosis of anemias. However, the number of articles mentioning about the relationship between RDW and human disorders has increased over the past decades. In tranplantation practice, the peripheral blood is the most common source of hematopoietic stem cells. There are many factors affecting the success of stem cell mobilization.
Aims
In this study, we tried to find a relationship between increased RDW and CD34+ cell count in the harvest.
Methods
Fifty patients who underwent stem cell mobilization between March 2014 and October 2015 are included in the study. Mean age was 56.82± 10 years, 28 (%56) patients were male and 22 (%44) patients were female. Diagnosis were multiple myeloma (n=32), non Hodgkin lymphoma (n=9), Hodgkin lymphoma (n=6), primary amyloidosis (n=1), Waldenstrom’s macroglobulinemia (n=1) and testicular carcinoma (n=1). Mobilization regimens were cyclophosphamide plus G-CSF in 35 (%70) patients, G-CSF alone in 2 (%4) patients, etoposide plus G-CSF in 2 (%4) patients and salvage chemotherapy plus G-CSF in 11 (%22) patients. Five (%10) patients had a history of radiotherapy. Bone marrow infiltration for patients except myeloma was found in 6 (%35) patients. Patients received mean 1.61± 0.6 lines and 4.94±2.6 courses of chemotherapy.
Results
RDW was not correlated with peripheral blood CD34+ cell count (r=0.064, p=0.75, n=28) and CD34+ cell count in the harvest (r=-0.14, p=0.34, n=50). Other parameters previously reported to affect stem cell mobilization (age, weight, number of chemotherapy courses before mobilization, hemoglobin, white blood cell count, absolute neutrophil count, absolute lymphocyte count, platelet count, albumin, LDH) were also evaluated. Peripheral blood CD34+ cell count (r=0.694, p=0.001, n=50) and the number of chemotherapy courses before mobilization (r=-0.451, p=0.008, n=28) were found as the only parameters that affect CD34+ cell count in the harvest. In order to assess the effect of increased RDW on the CD34+ cell count in the harvest; above 16 was set as a cut-off for increased RDW and patients were divided into 2 groups. Sex, primary diagnosis, stage, bone marrow infiltration, mobilization regimen, chemotherapy courses, radiotherapy, comorbidities, number of leukapheresis days were not different between two groups. LDH was the only parameter different between 2 groups. It was found higher in the increased RDW group (p=0.005). Although peripheral blood CD34+ cell count and CD34+ cell count in the harvest were not different statistically between 2 groups, the numbers were lower in the increased RDW group (10.48±5.94 vs 8.07±5.01).RDW was not correlated with peripheral blood CD34+ cell count and CD34+ cell count in the harvest in both groups.
Conclusion
To our knowledge, this is the first study evaluating the relationship between RDW and stem cell mobilization in cancer patients. Although it has not been definitely established, it seems reasonable to suggest using RDW far beyond the differential diagnosis of anemias. Stem cell mobilization can be a potential candidate in this era.
Session topic: E-poster
Keyword(s): CD34+ cells, Stem cell mobilization
{{ help_message }}
{{filter}}